logo
Plus   Neg
Share
Email

Regeneron Pharma Reports Positive Phase 3 Results For Evinacumab - Quick Facts

Regeneron Pharmaceuticals, Inc. (REGN) said a Phase 3 study of evinacumab in patients with homozygous familial hypercholesterolemia met its primary endpoint. In the trial, the investigational angiopoietin-like 3 antibody, when added to other lipid-lowering therapies, decreased LDL cholesterol by 49% on average, compared to lipid-lowering therapies alone. In the study, evinacumab was well-tolerated.

The company said the detailed results from the trial will be presented at a future medical meeting. Data will be submitted to regulatory authorities, with the FDA in 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Millennials and Generation Zs, or people aged between 18 to 34 year, pay more for car repairs, according to a new survey. The average American spent $1,986 over the past five years on vehicle repairs and maintenance, according to a survey by Ally Financial conducted by Harris Poll. However, among... Gap Inc.'s (GPS) Old Navy brand announced plans to open 800 new stores as part of its upcoming split from its parent company. "We'll almost double our fleet to 2,000 stores in North America, predominantly in under-served small markets," Old Navy CEO Sonia Syngal said. The company said the plan was... Google has launched a new website called 'Recover Together,' a resource intended to help people recover from addiction or substance use disorder. The new service was launched by the search giant in recognition of the National Recovery Month in September. Google noted that more than 23 million Americans are recovering from addiction, while 20 million are still struggling to seek treatment.
Follow RTT